Pro Investor research
Sign in to continue.
Full company research for this company is part of the Pro Investor membership: Pro Investor Scores and rankings, the full screener, valuation and capital returns intelligence, ownership and insider evidence, signals and alerts. Company identity, coverage depth and the education library stay free.
AMPH · NASDAQ
AMPHASTAR PHARMACEUTICALS INC
Private betaSector unavailable · Industry unavailable
$23.78
+1.02%
Close on Sep 11, 2026
Updated date unavailable
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Appears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
What this company does
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST .
Our largest products by net revenues currently include BAQSIMI glucagon nasal powder, or BAQSIMI , Primatene MIST , glucagon, epinephrine, and lidocaine.
In June 2023, we completed our acquisition of BAQSIMI , the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes, and it is currently available in the United States and 26 international markets.
In May 2024, the FDA approved our albuterol sulfate inhalation aerosol, which we launched in August 2024.
Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.